Rabeprazole (CAS 117976-89-3)
See product citations (2)
QUICK LINKS
Rabeprazole, a proton pump inhibitor (PPI), effectively lowers stomach acid production to alleviate conditions such as gastroesophageal reflux disease (GERD), ulcers, and other issues caused by excessive acid production. It belongs to the benzimidazole derivative family, sharing a structural similarity with omeprazole, another PPI. This white to off-white powder dissolves readily in water and weighs 376.41 g/mol. Rabeprazole hampers the activity of the gastric proton pump responsible for acid production. By binding to the pump, it obstructs the release of hydrogen ions into the stomach, ultimately reducing acid production. Furthermore, rabeprazole exhibits various biochemical and physiological effects. A study conducted on rats revealed that rabeprazole effectively decreases the gastric proton pump′s activity, leading to a decrease in gastric acid secretion.
Rabeprazole (CAS 117976-89-3) References
- Review article: the pharmacology of rabeprazole. | Williams, MP. and Pounder, RE. 1999. Aliment Pharmacol Ther. 13 Suppl 3: 3-10. PMID: 10491723
- Review article: the pharmacokinetics of rabeprazole in health and disease. | Swan, SK., et al. 1999. Aliment Pharmacol Ther. 13 Suppl 3: 11-7. PMID: 10491724
- Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. | Fuhr, U. and Jetter, A. 2002. Pharmazie. 57: 595-601. PMID: 12369444
- Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. | Gisbert, JP., et al. 2003. Aliment Pharmacol Ther. 17: 751-64. PMID: 12641497
- Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. | Sloan, S. 2003. Am J Gastroenterol. 98: S49-55. PMID: 12644031
- Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. | Li, XQ., et al. 2004. Drug Metab Dispos. 32: 821-7. PMID: 15258107
- Rabeprazole: a pharmacologic and clinical review for acid-related disorders. | Dadabhai, A. and Friedenberg, FK. 2009. Expert Opin Drug Saf. 8: 119-26. PMID: 19236223
- Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview. | Dash, RP., et al. 2018. Xenobiotica. 48: 422-432. PMID: 28294690
- Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD. | Yokoya, Y., et al. 2019. J Gastroenterol. 54: 1083-1095. PMID: 31396703
- Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole. | Abed, MN., et al. 2020. Pharmacology. 105: 645-651. PMID: 32289807
- Rabeprazole: A comprehensive profile. | Bakheit, AH., et al. 2021. Profiles Drug Subst Excip Relat Methodol. 46: 137-183. PMID: 33461697
- Rabeprazole Promotes Vascular Repair and Resolution of Sepsis-Induced Inflammatory Lung Injury through HIF-1α. | Evans, CE., et al. 2022. Cells. 11: PMID: 35563731
- Rabeprazole destroyed gastric epithelial barrier function through FOXF1/STAT3-mediated ZO-1 expression. | Yang, F., et al. 2023. Clin Exp Pharmacol Physiol. 50: 516-526. PMID: 36897043
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rabeprazole, 10 mg | sc-204872 | 10 mg | $349.00 | |||
Rabeprazole, 25 mg | sc-204872A | 25 mg | $620.00 |